In a major step toward advancing Pakistan’s health and pharmaceutical sector, Federal Minister for National Health Services, Regulations and Coordination, Syed Mustafa Kamal, held a high-level meeting with the CEOs of leading Chinese and German pharmaceutical companies to explore collaboration in local medicine production, technology transfer, and export development.
The discussions focused on building local manufacturing capacity and introducing cutting-edge pharmaceutical technologies to Pakistan. The German pharmaceutical company briefed the Minister on its ongoing projects in diabetes treatment and reaffirmed its long-term commitment to the country’s health industry.
Representatives from the Chinese pharmaceutical company expressed their intent to assist Pakistan through research collaboration, low-cost and high-quality technology transfer. They announced plans to establish a state-of-the-art production and manufacturing facility for pre-filled syringes, Semaglutide tablets, and GLP-1 (Ozempic/Monjaro) injections and cartridges, with an initial capital investment of USD 10 million.
Minister Mustafa Kamal highlighted Pakistan’s growing role as a regional export hub for pharmaceuticals, serving markets in Afghanistan, Central Asia, Africa, and beyond. He welcomed the proposed investments and invited both companies to submit a phased investment and implementation plan, assuring full regulatory and procedural support from the Government of Pakistan.
He emphasized that the government’s vision is to shift Pakistan from an importing country to an exporting nation in pharmaceuticals by attracting foreign investment, promoting innovation, and encouraging local production.
The CEO of DRAP assured continued facilitation for all necessary discussions and approvals, both through in-person and virtual meetings.
The meeting concluded with mutual appreciation and a shared commitment to work together for a stronger, self-reliant, and export-oriented pharmaceutical industry in Pakistan.
